Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

Rhea-AI Summary

Clearside Biomedical, a biopharmaceutical company focused on vision restoration, will participate in two investor conferences in March 2021. The first is the Cowen 41st Annual Health Care Conference on March 2, at 2:10 pm ET, focusing on clinical development. The second event is the 33rd Annual ROTH Conference on March 16, at 9:00 am ET, featuring an ophthalmology panel. Both panels will be accessible online, and management will engage in live, virtual one-on-one meetings with registered investors.

News Market Reaction – CLSD

-7.89%

-7.89% Session move

In the trading session that priced this news, CLSD declined 7.89%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021:

Cowen 41st Annual Health Care Conference
Blazing New Paths in Clinical Development and Structure Panel
Tuesday, March 2, 2021 at 2:10 pm ET

33rd Annual ROTH Conference
Ophthalmology Panel
Tuesday, March 16, 2021 at 9:00 am ET

The panels will be available for attendees on the conference websites. Management will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conferences.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector^® targets the suprachoroidal space (SCS^®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

What are the dates of the upcoming investor conferences for Clearside Biomedical?

Clearside Biomedical will participate in investor conferences on March 2 and March 16, 2021.

What time is the Cowen 41st Annual Health Care Conference scheduled for Clearside Biomedical?

The Cowen 41st Annual Health Care Conference is scheduled for March 2, 2021, at 2:10 pm ET.

What is the focus of the 33rd Annual ROTH Conference where Clearside Biomedical will participate?

The focus of the 33rd Annual ROTH Conference is ophthalmology.

Will Clearside Biomedical's conference panels be available for public viewing?

Yes, the panels will be available for attendees on the conference websites.

What is the purpose of Clearside Biomedical's participation in these conferences?

The purpose is to engage with investors through panels and live, virtual one-on-one meetings.